文献速递妇科

确定紫杉醇联合固定剂量顺铂用于卵巢癌腹腔热灌注化疗的最大耐受剂量:一项多中心Ⅰ期试验

Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial.
PubMed 文献 · Gynecol Oncol · 2023-12-30

该多中心Ⅰ期试验采用贝叶斯最优区间设计,确定紫杉醇联合固定剂量顺铂(75 mg/m2)用于卵巢癌腹腔热灌注化疗的最大耐受剂量,目标剂量限制性毒性率为25%。21例患者参与,175 mg/m2组12例可评估患者中2例报告剂量限制性毒性,该剂量被选为最大耐受剂量。结论认为在肿瘤细胞减灭术后接受腹腔热灌注化疗(43°C,90分钟)的患者中,紫杉醇可按175 mg/m2安全腹腔给药。

要点

  • 最大耐受剂量为紫杉醇175 mg/m2联合顺铂75 mg/m2。
  • 175 mg/m2组12例可评估患者中2例报告剂量限制性毒性。
  • 200 mg/m2组6例可评估患者中4例报告剂量限制性毒性。

核心结论

  • 紫杉醇联合固定剂量顺铂(75 mg/m2)在卵巢癌患者接受肿瘤细胞减灭术后腹腔热灌注化疗(43°C,90分钟)时,可按175 mg/m2安全腹腔给药。

研究设计与样本

  • 多中心Ⅰ期试验,采用贝叶斯最优区间设计。
  • 目标剂量限制性毒性率为25%,起始剂量175 mg/m2。
  • 数据与安全监察委员会以25 mg/m2为增量决定剂量递增或递减,最大样本量为30例或某剂量下治疗12例患者。

主要发现

  • 21例患者参与研究。
  • 150 mg/m2组3例可评估患者中未观察到剂量限制性毒性。
  • 175 mg/m2组12例可评估患者中2例报告剂量限制性毒性:1例4级中性粒细胞减少,1例4级贫血、中性粒细胞减少和白细胞减少。
  • 200 mg/m2组6例可评估患者中4例报告剂量限制性毒性:1例4级腹泻,1例3级肾损伤,2例4级贫血。
  • 175 mg/m2剂量组的剂量限制性毒性率等渗估计值为0.17(95%置信区间,0.02-0.42),该剂量被选为最大耐受剂量。

关键数值与推荐

  • 最大耐受剂量为紫杉醇175 mg/m2联合顺铂75 mg/m2。
  • 175 mg/m2组剂量限制性毒性率等渗估计值为0.17(95%置信区间,0.02-0.42)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the maximum tolerated dose (MTD) of paclitaxel combined with a fixed dose of cisplatin (75 mg/m2) delivered via hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with ovarian cancer. METHODS: This multicenter Phase I trial employed a Bayesian Optimal Interval (BOIN) design. The MTD was determined to have a target dose-limiting toxicity (DLT) rate of 25%. The starting dose was 175 mg/m2. The Data and Safety Monitoring Board made decisions regarding dose escalation or de-escalation in increments of 25 mg/m2 for subsequent patient cohorts, up to a maximum sample size of 30 or 12 patients treated at a given dose. RESULTS: Twenty-one patients participated in this study. Among the three evaluable patients who received 150 mg/m2 paclitaxel, no DLTs were observed. Among the 12 evaluable patients who received 175 mg/m2 paclitaxel, two reported DLTs: one had grade 4 neutropenia and one had grade 4 anemia, neutropenia, and leukopenia. Four of the six evaluable patients who received 200 mg/m2 paclitaxel reported DLTs: one patient had grade 4 diarrhea, one had grade 3 kidney injury, and two had grade 4 anemia. The isotonic estimate of the DLT rate in the 175 mg/m2 dose group was 0.17 (95% confidence interval, 0.02-0.42), and this dose was selected as the MTD. CONCLUSION: Paclitaxel, when combined with a fixed dose of cisplatin (75 mg/m2), can be safely administered intraperitoneally at a dose of 175 mg/m2 in patients with ovarian cancer who received HIPEC (43 °C, 90 min) following cytoreductive surgery.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wu MF, Cheng XY, Wang DY, et al. Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial. Gynecol Oncol. 2023. PMID: 38159362. doi:10.1016/j.ygyno.2023.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。